Antibiotic resistance – current landscape and combination therapy

Why is antibiotic resistance a global threat?

The challenges of antibiotic resistance, the current situation that marks it as a WHO priority and the potential of customized therapy are some of the issues that the CEO of Symcel, Dr Jesper Ericsson, discussed with GEN in a recent article.


Jesper talks about the situation in the EU and Sweden, the need for new antimicrobials, but also the solution of using existing antibiotics in combination, in order to customize treatments for each infection.


Symcel’s technology and Horizon 2020 project are also highlighted, as the calScreener™ has a unique approach for determining antibiotics synergy.


Read the article here.